Quantum Biopharma Stock Performance
| QNTM Stock | 3.99 0.21 5.00% |
The company holds a Beta of 1.97, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Quantum BioPharma will likely underperform. At this point, Quantum BioPharma has a negative expected return of -0.85%. Please make sure to check Quantum BioPharma's total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Quantum BioPharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Quantum BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 7.14 | Five Day Return 3.7 | Year To Date Return (40.09) | Ten Year Return (99.63) | All Time Return (99.63) |
Last Split Factor 1:65 | Last Split Date 2024-08-15 |
1 | Investigative News Program W5 Airs Final Segment on USD 700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC | 12/01/2025 |
2 | World Renowned Law Firm Grant Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum Bi... | 12/24/2025 |
3 | Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. Shareholders - The Globe and Mail | 12/31/2025 |
4 | Bronstein, Gewirtz Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act Class Action Filed Alleging Investor Harm | 01/05/2026 |
5 | CONTACTINVESTOR ALERT Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadli... | 01/20/2026 |
6 | Quantum Biopharma Rating Lowered to Sell at Wall Street Zen | 01/26/2026 |
| Begin Period Cash Flow | 2.8 M | |
| Total Cashflows From Investing Activities | -1.5 M |
Quantum BioPharma Relative Risk vs. Return Landscape
If you would invest 862.00 in Quantum BioPharma on November 11, 2025 and sell it today you would lose (468.00) from holding Quantum BioPharma or give up 54.29% of portfolio value over 90 days. Quantum BioPharma is currently does not generate positive expected returns and assumes 9.5079% risk (volatility on return distribution) over the 90 days horizon. In different words, 85% of stocks are less volatile than Quantum, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Quantum BioPharma Target Price Odds to finish over Current Price
The tendency of Quantum Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.99 | 90 days | 3.99 | about 97.0 |
Based on a normal probability distribution, the odds of Quantum BioPharma to move above the current price in 90 days from now is about 97.0 (This Quantum BioPharma probability density function shows the probability of Quantum Stock to fall within a particular range of prices over 90 days) .
Quantum BioPharma Price Density |
| Price |
Predictive Modules for Quantum BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Quantum BioPharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Quantum BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Quantum BioPharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Quantum BioPharma is not an exception. The market had few large corrections towards the Quantum BioPharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Quantum BioPharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Quantum BioPharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.15 | |
β | Beta against Dow Jones | 1.97 | |
σ | Overall volatility | 1.87 | |
Ir | Information ratio | -0.11 |
Quantum BioPharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Quantum BioPharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Quantum BioPharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Quantum BioPharma generated a negative expected return over the last 90 days | |
| Quantum BioPharma has high historical volatility and very poor performance | |
| Quantum BioPharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (14.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quantum BioPharma generates negative cash flow from operations | |
| Quantum BioPharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Bronstein, Gewirtz Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act Class Action Filed Alleging Investor Harm |
Quantum BioPharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Quantum Stock often depends not only on the future outlook of the current and potential Quantum BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Quantum BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 7.2 M |
Quantum BioPharma Fundamentals Growth
Quantum Stock prices reflect investors' perceptions of the future prospects and financial health of Quantum BioPharma, and Quantum BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Quantum Stock performance.
| Return On Equity | -2.51 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 17.45 M | ||||
| Shares Outstanding | 3.84 M | ||||
| Price To Book | 1.84 X | ||||
| Price To Sales | 91.86 X | ||||
| EBITDA | (14.38 M) | ||||
| Net Income | (14.92 M) | ||||
| Total Debt | 824.92 K | ||||
| Book Value Per Share | 2.27 X | ||||
| Cash Flow From Operations | (6.88 M) | ||||
| Earnings Per Share | (9.55) X | ||||
| Market Capitalization | 16.14 M | ||||
| Total Asset | 17.12 M | ||||
| Retained Earnings | (172.11 M) | ||||
| Working Capital | 5.37 M | ||||
About Quantum BioPharma Performance
By examining Quantum BioPharma's fundamental ratios, stakeholders can obtain critical insights into Quantum BioPharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Quantum BioPharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 114.26 | 101.57 | |
| Return On Tangible Assets | (1.05) | (1.10) | |
| Return On Capital Employed | (1.78) | (1.87) | |
| Return On Assets | (0.75) | (0.78) | |
| Return On Equity | (1.42) | (1.35) |
Things to note about Quantum BioPharma performance evaluation
Checking the ongoing alerts about Quantum BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Quantum BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Quantum BioPharma generated a negative expected return over the last 90 days | |
| Quantum BioPharma has high historical volatility and very poor performance | |
| Quantum BioPharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (14.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quantum BioPharma generates negative cash flow from operations | |
| Quantum BioPharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Bronstein, Gewirtz Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act Class Action Filed Alleging Investor Harm |
- Analyzing Quantum BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Quantum BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Quantum BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Quantum BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Quantum BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Quantum BioPharma's stock. These opinions can provide insight into Quantum BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quantum BioPharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Biotechnology sector continue expanding? Could Quantum diversify its offerings? Factors like these will boost the valuation of Quantum BioPharma. Anticipated expansion of Quantum directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Quantum BioPharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Quantum BioPharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Quantum BioPharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Quantum BioPharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.